DE69732407D1 - Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren - Google Patents

Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren

Info

Publication number
DE69732407D1
DE69732407D1 DE69732407T DE69732407T DE69732407D1 DE 69732407 D1 DE69732407 D1 DE 69732407D1 DE 69732407 T DE69732407 T DE 69732407T DE 69732407 T DE69732407 T DE 69732407T DE 69732407 D1 DE69732407 D1 DE 69732407D1
Authority
DE
Germany
Prior art keywords
influenza
replication
cell culture
influenza viruses
viruses made
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69732407T
Other languages
English (en)
Other versions
DE69732407T3 (de
DE69732407T2 (de
Inventor
Albrecht Groener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines GmbH
Original Assignee
Chiron Behring GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7790127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69732407(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Behring GmbH and Co KG filed Critical Chiron Behring GmbH and Co KG
Priority to DE122007000082C priority Critical patent/DE122007000082I1/de
Publication of DE69732407D1 publication Critical patent/DE69732407D1/de
Application granted granted Critical
Publication of DE69732407T2 publication Critical patent/DE69732407T2/de
Publication of DE69732407T3 publication Critical patent/DE69732407T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69732407.9T 1996-04-01 1997-04-01 Verfahren für die Replikation von Influenza in Zellkultur und die bei diesem Verfahren hergestellten Influenza-Viren Expired - Lifetime DE69732407T3 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE122007000082C DE122007000082I1 (de) 1996-04-01 1997-04-01 Verfahren für die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19612967 1996-04-01
DE19612967A DE19612967A1 (de) 1996-04-01 1996-04-01 Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
PCT/IB1997/000404 WO1997037001A1 (en) 1996-04-01 1997-04-01 Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
EP97915628.8A EP0891420B2 (de) 1996-04-01 1997-04-01 Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren

Publications (3)

Publication Number Publication Date
DE69732407D1 true DE69732407D1 (de) 2005-03-10
DE69732407T2 DE69732407T2 (de) 2006-01-19
DE69732407T3 DE69732407T3 (de) 2014-07-10

Family

ID=7790127

Family Applications (3)

Application Number Title Priority Date Filing Date
DE19612967A Withdrawn DE19612967A1 (de) 1996-04-01 1996-04-01 Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE122007000082C Pending DE122007000082I1 (de) 1996-04-01 1997-04-01 Verfahren für die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren
DE69732407.9T Expired - Lifetime DE69732407T3 (de) 1996-04-01 1997-04-01 Verfahren für die Replikation von Influenza in Zellkultur und die bei diesem Verfahren hergestellten Influenza-Viren

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE19612967A Withdrawn DE19612967A1 (de) 1996-04-01 1996-04-01 Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE122007000082C Pending DE122007000082I1 (de) 1996-04-01 1997-04-01 Verfahren für die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren

Country Status (13)

Country Link
US (2) US20030119183A1 (de)
EP (3) EP1526172B1 (de)
JP (6) JP4447054B2 (de)
AT (2) ATE513905T1 (de)
CA (1) CA2250078C (de)
DE (3) DE19612967A1 (de)
DK (2) DK0891420T4 (de)
ES (3) ES2236799T5 (de)
HK (2) HK1075467A1 (de)
LU (1) LU91381I2 (de)
NL (1) NL300307I1 (de)
PT (2) PT891420E (de)
WO (1) WO1997037001A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
WO1999023206A1 (en) * 1997-10-31 1999-05-14 Merck & Co., Inc. A method of improved mixing of a varicella-infected cell culture in roller bottles
CA2308111C (en) * 1997-10-31 2010-12-21 Merck & Co., Inc. A method of improved mixing in roller bottles
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
DE60142506D1 (de) 2000-03-03 2010-08-19 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
KR20050044523A (ko) * 2001-11-19 2005-05-12 벡톤 디킨슨 앤드 컴퍼니 입자 형태의 약제학적 조성물
DE50211123D1 (de) 2002-09-16 2007-12-06 Pan Biotech Gmbh Verfahren zur kultivierung von zellen, insbesondere menschlicher oder tierischer zellen
WO2004033616A1 (de) * 2002-09-16 2004-04-22 Pan-Biotech Gmbh Einrichtung zur kultivierung von zellen, insbesondere menschlicher oder tierischer zellen
AU2004249802B2 (en) 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
JP5600375B2 (ja) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド インフルエンザウイルスワクチン
CN101094915A (zh) * 2004-05-20 2007-12-26 益得生物医学公司 生产流感疫苗的方法
EP2811027A1 (de) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus-Vektoren für RSV- und PIV-Impfstoffe
DE602005024827D1 (de) * 2004-09-09 2010-12-30 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
AU2005314138B2 (en) 2004-12-08 2011-11-17 Medimmune, Llc Methods of producing influenza vaccine compositions
EP1831353B1 (de) 2004-12-23 2012-02-29 MedImmune, LLC Nichttumorbildende mdck-zellinie zur vermehrung von viren
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
NZ567817A (en) 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
EA014028B1 (ru) 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DK1976559T6 (da) 2006-01-27 2020-04-06 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
EP2004226A1 (de) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Lagerung von grippeimpfstoffen ohne kühlung
US9254318B2 (en) 2006-03-31 2016-02-09 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
WO2007132763A1 (ja) * 2006-05-11 2007-11-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute インフルエンザウイルスの増殖方法
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2663196A1 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
WO2008105931A2 (en) 2006-09-15 2008-09-04 Medimmune Vaccines, Inc. Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
WO2008135230A1 (en) * 2007-05-04 2008-11-13 Baxter International Inc. Two-step temperature profile for the propagation of viruses
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
EP2268309B1 (de) 2008-03-18 2015-01-21 Novartis AG Verbesserungen der herstellung von grippevirus-impstoff-antigenen
CN102216450B (zh) 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
JP2012517416A (ja) 2009-02-10 2012-08-02 ノバルティス アーゲー 増加した量のh3抗原を含むインフルエンザワクチン
US20120093859A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
SI2401384T1 (sl) 2009-05-21 2013-01-31 Novartis Ag Reverzna genetika z uporabo neendogenih pol i promotorjev
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CA2769673A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
AU2010309404B2 (en) 2009-10-20 2015-07-09 Seqirus UK Limited Improved reverse genetics methods for virus rescue
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
EP2531592A1 (de) 2010-02-04 2012-12-12 Vivalis Fed-batch-verfahren mit konzentriertem zellkulturmedium zur effizienten produktion von biologischen wirkstoffen bei eb66-zellen
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US20130203151A1 (en) 2010-04-26 2013-08-08 Scott Balsitis Production of alphavirus replicon particles in packaging cells
EP2571520B1 (de) 2010-05-21 2018-04-04 Seqirus UK Limited Methode für das influenza-reassortment
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
JP5976639B2 (ja) 2010-06-01 2016-08-23 ノバルティス アーゲー インフルエンザワクチン抗原の濃縮および凍結乾燥
AU2011290471B2 (en) 2010-08-20 2015-08-20 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
ES2716243T3 (es) 2010-10-11 2019-06-11 Glaxosmithkline Biologicals Sa Plataformas de suministro de antígenos
EP3527224A1 (de) 2011-01-26 2019-08-21 GlaxoSmithKline Biologicals S.A. Rsv-immunisierungstherapie
CA2829774C (en) 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
EP2768530A1 (de) 2011-10-11 2014-08-27 Novartis AG Rekombinante polycistronische selbstreplizierende rna-moleküle
WO2013054199A2 (en) 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
AU2013205478B9 (en) 2012-03-02 2014-11-20 Seqirus UK Limited Influenza virus reassortment
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
AU2013270793A1 (en) 2012-06-04 2014-12-11 Novartis Ag Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
AU2013354219A1 (en) 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren
WO2014141125A2 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
EP2801372A3 (de) 2013-05-10 2015-02-18 Novartis AG Narkolepsierisikovermeidung bei Influenza-Impfstoffen
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
MX2015016755A (es) 2013-06-06 2016-04-13 Novartis Ag Reagrupamiento del virus de influenza.
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
HUE051783T2 (hu) 2015-07-07 2021-03-29 Seqirus Uk Ltd Eljárás immunogén hemagglutinin mennyiségi meghatározására
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
MX2020004543A (es) 2017-11-03 2020-09-18 Takeda Vaccines Inc Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
JP2022527235A (ja) 2019-01-23 2022-06-01 義裕 河岡 インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異
JP2022522112A (ja) 2019-02-08 2022-04-14 ウィスコンシン アルムニ リサーチ ファンデイション ヒト化細胞系
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2020226831A1 (en) 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
JP2022551805A (ja) 2019-08-27 2022-12-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたhaを持つ組換えインフルエンザウイルス
IL293031A (en) 2019-11-18 2022-07-01 Seqirus Pty Ltd A method for producing reassortant influenza viruses
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278075B (de) * 1964-06-22 1968-09-19 Norden Lab Inc Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CA1122527A (en) * 1979-05-15 1982-04-27 Karen K. Brown Influenza vaccine production in liquid cell culture
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
USRE33164E (en) * 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
US4783411A (en) * 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5646033A (en) * 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US6514502B1 (en) * 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells

Also Published As

Publication number Publication date
DK0891420T4 (da) 2014-01-20
CA2250078A1 (en) 1997-10-09
PT1526172E (pt) 2011-09-01
EP0891420A1 (de) 1999-01-20
EP0891420B2 (de) 2013-11-20
DE19612967A1 (de) 1997-10-02
DK0891420T3 (da) 2005-04-25
LU91381I2 (fr) 2008-01-30
WO1997037001A1 (en) 1997-10-09
HK1142093A1 (en) 2010-11-26
JP4447054B2 (ja) 2010-04-07
PT891420E (pt) 2005-06-30
DK1526172T3 (da) 2011-10-03
ES2435726T3 (es) 2013-12-23
ES2367081T3 (es) 2011-10-28
ATE288479T1 (de) 2005-02-15
US20030119183A1 (en) 2003-06-26
JP2000507825A (ja) 2000-06-27
DE69732407T3 (de) 2014-07-10
JP2006296437A (ja) 2006-11-02
JP2010275321A (ja) 2010-12-09
CA2250078C (en) 2009-06-23
EP0891420B1 (de) 2005-02-02
EP1526172A1 (de) 2005-04-27
ATE513905T1 (de) 2011-07-15
ES2236799T5 (es) 2014-01-23
DE122007000082I1 (de) 2009-01-02
NL300307I1 (nl) 2008-02-01
JP2013116124A (ja) 2013-06-13
JP2008245659A (ja) 2008-10-16
JP5264843B2 (ja) 2013-08-14
ES2236799T3 (es) 2005-07-16
JP2011212020A (ja) 2011-10-27
EP2172543A1 (de) 2010-04-07
HK1075467A1 (en) 2005-12-16
US20070117131A1 (en) 2007-05-24
EP2172543B1 (de) 2013-08-21
DE69732407T2 (de) 2006-01-19
EP1526172B1 (de) 2011-06-22

Similar Documents

Publication Publication Date Title
DE69732407D1 (de) Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
BR9707948A (pt) Processo para obter plantas transplastômicas
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
GR890100846A (el) Μεθοδος μετατροπης κυτταρικης διαφοροποιησης και λειτουργιας καισυνθεσεις της.
DE59507481D1 (de) Verfahren zur Herstellung von aliphatischen alpha, omega-Diolen
DE69005987D1 (de) Dichtung, Vorrichtung und Verfahren zur ihrer Herstellung.
DE3877711D1 (de) Antibeschlagzusammensetzung, damit beschichtetes produkt und verfahren zu dessen herstellung.
DE68923171D1 (de) Aluminiumhydroxyd, verfahren zur herstellung und zusammensetzung.
DE69009614D1 (de) Verfahren zur Herstellung von (S)-gamma-Hydroxymethyl-alpha,beta-Butenolid.
DE3576361D1 (de) Rekombinante dna, damit transformierter mikroorganismus, und verfahren zur herstellung von menschlicher cu-zn superoxiddismutase unter verwendung des transformierten mikroorganismus.
DE59001156D1 (de) Verfahren zur herstellung von muscon, zwischenprodukte fuer dieses verfahren sowie deren herstellung.
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69013132D1 (de) Verfahren zur Herstellung von Octa-2,7-dien-1-ol.
DE60136558D1 (de) Verfahren zur kultivierung humaner chondrozyten
BR0114884A (pt) Compostos calcilìticos
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
ATE231486T1 (de) Optisch aktive 2-amino-tetraline, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten und die nützlich sind zur vorbeugung und behandlung von septischem schock
DE69016857D1 (de) Verfahren zur Herstellung von NiNi-Diakyl- 1,8-Naphthalendiamin.
DE69008488D1 (de) Verfahren zur Herstellung von N-Alkylaminophenolen und von N,N-Dialkylaminophenolen.
DE58906998D1 (de) Verfahren zur Herstellung von 4,5,6-Trichlorpyrimidin.
DE69102611D1 (de) Verfahren zum Gerben von Proteinsubstanzen, insbesondere pflanzliche Proteinsubstanzen sowie ölige Proteine und nach diesem Verfahren hergestellte gegerbte Proteinsubstanzen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
V448 Application of spc

Free format text: PRODUCT NAME: INFLUENZA-IMPFSTOFF, DER AUS EINEM IN ZELLKULTUR ANGEZUECHTETEN INFLUENZA-VIRUS HERGESTELLT WIRD,WOBEI DIE ZELLEN FUER DIE VIRUSREPLIKATION BEI EINER TEMPERATUR IM BEREICH VON 30-36 GRAD C. KULTIVIERT WERDEN; REGISTRATION NO/DATE: EU/1/07/394/001 - EU/1/07/394/006; 20070601

Spc suppl protection certif: 12 2007 000 082

Filing date: 20071130

8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. K, DE

V454 Spc application withdrawn or to be regarded as withdrawn

Free format text: PRODUCT NAME: INFLUENZA-IMPFSTOFF, DER AUS EINEM IN ZELLKULTUR ANGEZUECHTETEN INFLUENZA-VIRUS HERGESTELLT WIRD,WOBEI DIE ZELLEN FUER DIE VIRUSREPLIKATION BEI EINER TEMPERATUR IM BEREICH VON 30/36 GRAD C. KULTIVIERT WERDEN; REGISTRATION NO/DATE: EU/1/07/394/001 - EU/1/07/394/006; 20070601

Spc suppl protection certif: 12 2007 000 082

Filing date: 20071130

8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, 35041 , DE